Merck KGaA

UiPath announced that Merck KGaA, Darmstadt, Germany is building a program for agentic software testing on UiPath Test Cloud, applying AI agents, automation and human oversight across the software testing lifecycle.

Partners: UiPath

Merck KGaA's Life Science business signed an MoU with Siemens; joint projects include developing AI-driven tools and digital interfaces that simplify complex scientific processes.

Partners: Siemens

Uncountable announced that Merck KGaA, Darmstadt, Germany selected its platform to digitalize its central analytical laboratories; Uncountable says the solution will improve data access to enable ML- and LLM-powered use cases.

Partners: Uncountable

Evinova announced a multi-year collaboration under which Merck KGaA, Darmstadt, Germany will adopt its AI-native platform across study design, document authoring and downstream automation in clinical development.

Partners: Evinova

Merck KGaA's 2025 annual report says the company also uses AIDDISON, its generative-AI discovery platform, internally in the Healthcare business for early-stage drug discovery.

Merck KGaA launched AIDDISON, drug discovery software that it says combines generative AI, machine learning and computer-aided drug design to speed up drug development.

Merck KGaA's 2025 annual report says myGPT Suite, its internal generative AI platform, has more than 32,000 active users a month (over half the workforce) and more than 90% cost savings versus off-the-shelf options.

Merck KGaA's 2025 annual report says its smartfacturing playbook, including modular manufacturing, AI energy optimization and predictive maintenance, cuts time to market by up to 50% and uses around 20% less energy at reference sites.

Merck KGaA and imec announced a partnership to develop a modular MPS-on-a-chip platform intended to simulate human body responses and provide high-quality training data for AI models in drug discovery.

Partners: imec